RATIONALE: Experimental evidence suggests that CDHR3 (cadherin-related family member 3) is a receptor for rhinovirus (RV)-C, and a missense variant in this gene (rs6967330) is associated with childhood asthma with severe exacerbations. OBJECTIVES: To determine whether rs6967330 influences RV-C infections and illnesses in early childhood. METHODS: We studied associations between rs6967330 and respiratory infections and illnesses in the COPSAC2010 (Copenhagen Prospective Studies on Asthma in Childhood 2010) and COAST (Childhood Origins of Asthma Birth Cohort Study) birth cohorts, where respiratory infections were monitored prospectively for the first 3 years of life. Nasal samples were collected during acute infections in both cohorts and during asymptomatic periods in COAST and analyzed for RV-A, RV-B, and RV-C, and other common respiratory viruses. MEASUREMENTS AND MAIN RESULTS: The CDHR3 asthma risk allele (rs6967330-A) was associated with increased risk of respiratory tract illnesses (incidence risk ratio [IRR] = 1.14 [95% confidence interval, 1.05-1.23]; P = 0.003). In particular, this variant was associated with risk of respiratory episodes with detection of RV-C in COPSAC2010 (IRR = 1.89 [1.14-3.05]; P = 0.01) and in COAST (IRR = 1.37 [1.02-1.82]; P = 0.03) children, and in a combined meta-analysis (IRR = 1.51 [1.13-2.02]; P = 0.006). In contrast, the variant was not associated with illnesses related to other viruses (IRR = 1.07 [0.92-1.25]; P = 0.37). Consistent with these observations, the CDHR3 variant was associated with increased detection of RV-C, but not of other viruses during scheduled visits at specific ages. CONCLUSIONS: The CDHR3 asthma risk allele is associated specifically with RV-C illnesses in two birth cohorts. This clinical evidence supports earlier molecular evidence indicating that CDHR3 functions as an RV-C receptor, and raises the possibility of preventing RV-C infections by targeting CDHR3.
RATIONALE: Experimental evidence suggests that CDHR3 (cadherin-related family member 3) is a receptor for rhinovirus (RV)-C, and a missense variant in this gene (rs6967330) is associated with childhood asthma with severe exacerbations. OBJECTIVES: To determine whether rs6967330 influences RV-C infections and illnesses in early childhood. METHODS: We studied associations between rs6967330 and respiratory infections and illnesses in the COPSAC2010 (Copenhagen Prospective Studies on Asthma in Childhood 2010) and COAST (Childhood Origins of Asthma Birth Cohort Study) birth cohorts, where respiratory infections were monitored prospectively for the first 3 years of life. Nasal samples were collected during acute infections in both cohorts and during asymptomatic periods in COAST and analyzed for RV-A, RV-B, and RV-C, and other common respiratory viruses. MEASUREMENTS AND MAIN RESULTS: The CDHR3 asthma risk allele (rs6967330-A) was associated with increased risk of respiratory tract illnesses (incidence risk ratio [IRR] = 1.14 [95% confidence interval, 1.05-1.23]; P = 0.003). In particular, this variant was associated with risk of respiratory episodes with detection of RV-C in COPSAC2010 (IRR = 1.89 [1.14-3.05]; P = 0.01) and in COAST (IRR = 1.37 [1.02-1.82]; P = 0.03) children, and in a combined meta-analysis (IRR = 1.51 [1.13-2.02]; P = 0.006). In contrast, the variant was not associated with illnesses related to other viruses (IRR = 1.07 [0.92-1.25]; P = 0.37). Consistent with these observations, the CDHR3 variant was associated with increased detection of RV-C, but not of other viruses during scheduled visits at specific ages. CONCLUSIONS: The CDHR3 asthma risk allele is associated specifically with RV-C illnesses in two birth cohorts. This clinical evidence supports earlier molecular evidence indicating that CDHR3 functions as an RV-C receptor, and raises the possibility of preventing RV-C infections by targeting CDHR3.
Authors: Desmond W Cox; Joelene Bizzintino; Giovanni Ferrari; Siew Kim Khoo; Guicheng Zhang; Siobhan Whelan; Wai Ming Lee; Yury A Bochkov; Gary C Geelhoed; Jack Goldblatt; James E Gern; Ingrid A Laing; Peter N Le Souëf Journal: Am J Respir Crit Care Med Date: 2013-12-01 Impact factor: 21.405
Authors: Yury A Bochkov; Kelly Watters; Shamaila Ashraf; Theodor F Griggs; Mark K Devries; Daniel J Jackson; Ann C Palmenberg; James E Gern Journal: Proc Natl Acad Sci U S A Date: 2015-04-06 Impact factor: 11.205
Authors: J Bizzintino; W-M Lee; I A Laing; F Vang; T Pappas; G Zhang; A C Martin; S-K Khoo; D W Cox; G C Geelhoed; P C McMinn; J Goldblatt; J E Gern; P N Le Souëf Journal: Eur Respir J Date: 2010-08-06 Impact factor: 16.671
Authors: Hans Bisgaard; Jakob Stokholm; Bo L Chawes; Nadja H Vissing; Elin Bjarnadóttir; Ann-Marie M Schoos; Helene M Wolsk; Tine M Pedersen; Rebecca K Vinding; Sunna Thorsteinsdóttir; Nilofar V Følsgaard; Nadia R Fink; Jonathan Thorsen; Anders G Pedersen; Johannes Waage; Morten A Rasmussen; Ken D Stark; Sjurdur F Olsen; Klaus Bønnelykke Journal: N Engl J Med Date: 2016-12-29 Impact factor: 91.245
Authors: Klaus Bønnelykke; Patrick Sleiman; Kasper Nielsen; Eskil Kreiner-Møller; Josep M Mercader; Danielle Belgrave; Herman T den Dekker; Anders Husby; Astrid Sevelsted; Grissel Faura-Tellez; Li Juel Mortensen; Lavinia Paternoster; Richard Flaaten; Anne Mølgaard; David E Smart; Philip F Thomsen; Morten A Rasmussen; Silvia Bonàs-Guarch; Claus Holst; Ellen A Nohr; Rachita Yadav; Michael E March; Thomas Blicher; Peter M Lackie; Vincent W V Jaddoe; Angela Simpson; John W Holloway; Liesbeth Duijts; Adnan Custovic; Donna E Davies; David Torrents; Ramneek Gupta; Mads V Hollegaard; David M Hougaard; Hakon Hakonarson; Hans Bisgaard Journal: Nat Genet Date: 2013-11-17 Impact factor: 38.330
Authors: Klaus Bønnelykke; Nadja Hawwa Vissing; Astrid Sevelsted; Sebastian L Johnston; Hans Bisgaard Journal: J Allergy Clin Immunol Date: 2015-04-21 Impact factor: 10.793
Authors: Kohei Hasegawa; Jonathan M Mansbach; Yury A Bochkov; James E Gern; Pedro A Piedra; Cindy S Bauer; Stephen J Teach; Susan Wu; Ashley F Sullivan; Carlos A Camargo Journal: JAMA Pediatr Date: 2019-06-01 Impact factor: 16.193
Authors: Mary B O'Neill; Guillaume Laval; João C Teixeira; Ann C Palmenberg; Caitlin S Pepperell Journal: Hum Mol Genet Date: 2020-03-27 Impact factor: 6.150
Authors: Spyridon Megremis; Katarzyna Niespodziana; Clarissa Cabauatan; Paraskevi Xepapadaki; Marek L Kowalski; Tuomas Jartti; Claus Bachert; Susetta Finotto; Peter West; Sofia Stamataki; Anna Lewandowska-Polak; Heikki Lukkarinen; Nan Zhang; Theodor Zimmermann; Frank Stolz; Angela Neubauer; Mübeccel Akdis; Evangelos Andreakos; Rudolf Valenta; Nikolaos G Papadopoulos Journal: Am J Respir Crit Care Med Date: 2018-12-15 Impact factor: 21.405